ReVIDA Recovery

What ReVIDA Recovery does

ReVIDA Recovery Centers is a private, for-profit outpatient behavioral healthcare operator founded in 2018 by Lee Dilworth and headquartered in Nashville, Tennessee. The company delivers Medication-Assisted Treatment (MAT) for Opioid Use Disorder (OUD) through a network of 14 clinic locations across Northeast Tennessee and Southwest Virginia, including Johnson City, Knoxville, Chattanooga, Abingdon, and Wytheville. Its clinical model combines FDA-approved buprenorphine-based medications — Suboxone (daily oral) and Sublocade (monthly extended-release injection) — with behavioral healthcare services including individual therapy, group therapy, family therapy, cognitive behavioral therapy (CBT), and care coordination for social determinants of health such as housing, employment, and transportation. Patient care is structured through the proprietary ReVIDA Advantage program, a three-phase framework (EQUIP, ELEVATE, BOOST) that adapts service intensity to real-time patient presentation rather than imposing a fixed duration.

ReVIDA generates revenue primarily through insurance reimbursement — commercial carriers (Anthem, BCBS TN, United Healthcare, Aetna, Cigna, Humana, Magellan), Medicaid managed care plans (Amerigroup, Virginia Premier, Optima, Molina, AmeriGroup), and Medicare — with patient responsibility varying by plan; several plans cover 100% of program costs. A 2025 Treatment for All program extends scholarships to uninsured and insured Tennessee residents. The go-to-market motion is sales-led: trained Admissions Specialists staff a toll-free line (423-631-0432), verify insurance, and schedule in-person assessments at the nearest clinic, with referrals sourced from community partners, healthcare providers, and self-referrals. Telehealth is offered to established patients for therapy and care coordination but not for initial intake.

The company is led by CEO and founder Lee Dilworth with CFO Evan Norton (ex-Raymond James Healthcare Services, Deloitte), COO Greg Phillips (ex-Pinnacle Treatment Centers), and CRO/CCO Lindsay Key (ex-Constellation Behavioral Health), under a Board chaired by Marty Rash, former CEO of RCCH HealthCare Partners. ReVIDA holds CARF accreditation, is licensed as a MAT Center in Tennessee and Virginia, and complies with 42 CFR Part 2 and HIPAA. Only $800,002 in disclosed funding (July 2019) has been raised, indicating a primarily bootstrapped growth model relative to PE-backed behavioral health peers.

Name

ReVIDA Recovery

Legal name

ReVIDA Recovery® Centers

Website

https://revidarecovery.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

ReVIDA Recovery is a private outpatient behavioral healthcare operator running 14 Medication-Assisted Treatment clinics for opioid use disorder across Northeast Tennessee and Southwest Virginia, combining buprenorphine-based pharmacotherapy with behavioral therapy under its ReVIDA Advantage phased-care framework.

Ownership category

akta.pro rank

Product category

Outpatient Addiction Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (62142), Other Individual and Family Services (624190)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro industry

PRIMARYBPAGAEAO

Substance Use Recovery & Harm Reduction Support Services

Business & Public Services/Nonprofit, NGO & Social Services/Social Services & Community Support (Food, Housing, Family)

Keywords

• Outpatient addiction treatment
• Opioid use disorder care
• Medication-assisted treatment
• Behavioral healthcare services
• Addiction recovery centers

Headquarters

HQ city

Johnson City

HQ country

United States

HQ region

North America

Offices15 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Healthcare Services Revenue: ReVIDA generates revenue through providing medication-assisted treatment and behavioral healthcare services to patients with opioid use disorder. Revenue is received from insurance payments (commercial insurance, Medicare, Medicaid), self-pay patients, and scholarship programs for qualifying uninsured Tennessee residents.
2. Insurance Reimbursement: The company participates with numerous insurance and managed care plans from Tennessee and Virginia. Various medical plans cover 100% of program costs. Patient responsibility varies based on insurance coverage.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

ReVIDA Recovery® Centers provides outpatient Medication-Assisted Treatment (MAT) for opioid use disorder across 12-14 clinics in Tennessee and Virginia. Services combine FDA-approved buprenorphine-based medications (Suboxone and Sublocade) with individual, group, and family behavioral therapy, care coordination for social-determinant needs, telehealth follow-up, and 12-step facilitation. Care is delivered through a proprietary phased framework called ReVIDA Advantage (EQUIP, ELEVATE, BOOST) with financials settled via commercial insurance, Medicare, Medicaid, self-pay, and Treatment for All scholarships.

Product overview

ReVIDA Recovery offers a unified outpatient treatment platform for opioid use disorder (OUD) centered on Medication-Assisted Treatment (MAT). The core portfolio includes two buprenorphine-based medications—Suboxone (daily oral tablet/film) and Sublocade (monthly extended-release injection)—supported by behavioral therapy services (individual, group, and family counseling), telehealth delivery, care coordination for social determinants of health, and 12-step program facilitation. These clinical services are coordinated through the ReVIDA Advantage framework, which structures patient care into three progressive phases (EQUIP, ELEVATE, BOOST). Financial barriers are addressed through a dedicated treatment scholarship program. The platform is delivered exclusively through in-person clinic visits and telehealth appointments, with no public API or technical integrations.

Differentiator

Problem solved

Functional benefit

Brands

• ReVIDA Advantage: A phased-based approach to care with three stages: EQUIP (introductory period for new patients), ELEVATE (recovery support services integration), and BOOST (strategies for obstacles and disruptions in recovery).

Products and services

• Medication-Assisted Treatment (MAT) Program Foundational outpatient treatment program that combines FDA-approved buprenorphine-based medications with behavioral therapy to treat opioid use disorder, addressing both physical withdrawal and psychological aspects of addiction for adult patients at ReVIDA Recovery clinics in Tennessee and Virginia.
• Suboxone Treatment Daily buprenorphine/naloxone medication delivered as a tablet or film to reduce opioid cravings and withdrawal symptoms, prescribed to adult patients enrolled in the ReVIDA Recovery MAT program.
• Sublocade Treatment Extended-release monthly buprenorphine injection administered in-clinic by a ReVIDA physician, forming a depot gel that releases consistent medication throughout the month and reducing the need for daily dosing, offered to adult patients in the MAT program.
• Behavioral Health Services Integrated individual, group, and family therapy using cognitive behavioral therapy (CBT) for patients in the MAT program, addressing root causes of opioid use disorder, co-occurring mental health conditions, and family/relationship impacts, plus facilitated 12-step AA/NA meetings held weekly at ReVIDA facilities.
• Telehealth Services Virtual care delivery for established ReVIDA Recovery patients offering individual therapy, group therapy, care coordination meetings, and physician check-ins via video to reduce transportation barriers and support at-home care access (initial assessment still requires in-person visit).
• Care Coordination Services Practical support connecting ReVIDA Recovery patients with resources for employment, housing, food assistance, transportation, court documentation, and other social-determinant-of-health needs that affect long-term recovery stability.
• ReVIDA Advantage Care Framework Proprietary phased approach to care with three sequential stages — EQUIP (introductory stabilization for new patients), ELEVATE (integration with recovery support services across health, home and community), and BOOST (strategies for facing obstacles and disruptions affecting recovery stability) — providing a motivational rather than punitive structure that adjusts service level to real-time patient presentation.
• Treatment for All Scholarship Program Financial assistance program offering treatment scholarships covering up to 100% of care costs for uninsured Tennessee residents and additional funds for insured patients to cover copays, deductibles, and coinsurance, removing cost barriers to MAT and behavioral healthcare.

Quantifiable outcome

• Treatment failure rate for daily Suboxone users is 25% compared to 100% for those who only took Suboxone during detox (NIH research cited)
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Ten partnerships are on record, tiered core and minor.

• Sullivan County Anti-Drug CoalitioncoreStrategic or Co-development PartnerWorking with the Sullivan County Anti-Drug Coalition, ReVIDA Recovery partnered with TDMHSAS Overdose Prevention Specialists to administer Naloxone Kits to patients at the Johnson City, TN location. This partnership provides free naloxone kits to help prevent overdose deaths in the community.
• Tennessee Association of Alcohol and Drug Abuse Service (TAADA)minorOthersReVIDA is a proud member of TAADA, participating in the substance abuse prevention and treatment community in Tennessee.
• NAADCminorOthersMember of the National Association of Alcohol and Drug Abuse Counselors, connecting with national standards and resources for addiction treatment.
• NACATSminorOthersMember of the National Association for Continuing and Postsecondary Addiction Education, supporting professional development and education in addiction treatment.
• Johnson City Community Health CentercoreStrategic or Co-development PartnerPartnership to provide primary care and dental services to ReVIDA patients, addressing broader healthcare needs alongside addiction treatment.
• ETSU Charitable PharmacyminorStrategic or Co-development PartnerPartnership providing access to HEP-C medication for patients in recovery.
• Tennessee Career CenterscoreStrategic or Co-development PartnerVocational assistance and job placement services to support employment needs of patients in recovery.
• Count It! Lock It! Drop It!minorStrategic or Co-development PartnerCommunity partnership to prevent accidental drug exposure through proper medication storage and disposal awareness.
• Metro Drug CoalitionminorStrategic or Co-development PartnerKnoxville-based anti-drug coalition partnership supporting community prevention efforts.
• Sullivan County Anti-Drug CoalitioncoreStrategic or Co-development PartnerCoalition partnership focused on anti-drug initiatives in Sullivan County, TN.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Emerging players

• Groups: Recover Together: Outpatient MAT provider using a group-therapy-centered buprenorphine model with multi-state clinic footprint. Comparable to ReVIDA on outpatient MAT core, with a distinct group-therapy emphasis and a tech-enabled intake/insurance workflow.

Direct peers

• CleanSlate Outpatient Addiction Medicine: Multi-state outpatient MAT provider specializing in buprenorphine treatment for opioid and alcohol use disorders. Operates a clinic-based delivery model highly comparable to ReVIDA's, including insurance participation and care coordination services.
• BrightView Health: Outpatient addiction treatment provider offering MAT, counseling, and telehealth across multiple states. Comparable to ReVIDA on outpatient MAT core, therapy integration, and care coordination, with a larger multi-state presence.
• Ideal Option: Outpatient MAT provider operating clinics across multiple U.S. states, focused on buprenorphine-based treatment for opioid dependence. Closely aligned with ReVIDA on core clinical model (Suboxone-centric MAT in clinic setting) and payer mix.
• Pinnacle Treatment Centers: Multi-state addiction treatment network offering outpatient MAT, residential, and detox services. Directly comparable to ReVIDA's outpatient MAT-plus-therapy model; notably, former ReVIDA COO Greg Phillips previously served as SVP at Pinnacle, indicating overlapping operating playbooks.
• BayMark Health Services: One of the largest U.S. outpatient opioid treatment providers, operating MAT programs (buprenorphine, methadone) across multiple states. Direct competitor to ReVIDA's Suboxone/Sublocade-based MAT model with broader geographic reach and similar multi-payer, clinic-based delivery.
• Spero Health: Outpatient addiction medicine provider with multi-state clinic footprint, primarily across the Mid-South and Appalachia, offering buprenorphine MAT and behavioral therapy. Overlaps with ReVIDA on geography (Tennessee, Virginia, Kentucky) and care model.
• Crossroads Treatment Centers: Outpatient MAT and addiction treatment provider with a large footprint in the Southeast and Mid-Atlantic. Direct overlap with ReVIDA on buprenorphine-centered MAT, in-clinic counseling, and regional payer participation.

Broad incumbents

• Acadia Healthcare: Large publicly traded behavioral health operator with residential and outpatient SUD treatment facilities across the U.S. While not exclusively focused on outpatient MAT, Acadia represents the broader incumbent landscape and potential acquirer/partner for scaled outpatient MAT operators like ReVIDA.

Regional players

• Center for Behavioral Health: Outpatient MAT and behavioral health provider with a strong multi-state presence concentrated in the Southeast and Midwest. Comparable to ReVIDA on clinic-based methadone/buprenorphine MAT delivery and Medicaid-heavy payer mix, with limited direct geographic overlap in TN/VA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/revida-recovery

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReVIDA Recovery